

# Selexipag

Catalog No: tcsc3774



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg



## Specifications

**CAS No:**

475086-01-2

**Formula:**

$C_{26}H_{32}N_4O_4S$

**Pathway:**

GPCR/G Protein

**Target:**

Prostaglandin Receptor

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 50$  mg/mL (100.68 mM); H<sub>2</sub>O :

**Alternative Names:**

NS-304;ACT-293987

**Observed Molecular Weight:**

496.62


## Product Description

Selexipag (NS-304) is an orally available and potent agonist for the Prostacyclin (**PGI<sub>2</sub>**) receptor (IP receptor).

IC<sub>50</sub> & Target: Prostacyclin receptor<sup>[1]</sup>

**In Vitro:** Selexipag (NS-304) is an orally available and long-acting IP receptor agonist prodrug, and its active form, MRE-269, is highly selective for the IP receptor. Selexipag (NS-304) inhibits the binding of [<sup>3</sup>H]Iloprost to the human and rat IP receptors in a concentration-dependent manner. The K<sub>i</sub> is 260 nM for the human IP receptor and 2100 nM for the rat IP receptor. The intracellular cAMP levels in hIP-CHO cells are increased in a concentration-dependent manner by treatment with Selexipag (NS-304) with EC<sub>50</sub> of 177nM. Selexipag (NS-304) also inhibits platelet aggregation in humans and monkeys with IC<sub>50</sub> values of 5.5 and 3.4 μM, respectively, but it shows no inhibition in dogs (IC<sub>50</sub> of >100 μM)<sup>[1]</sup>.

**In Vivo:** The C<sub>max</sub> of MRE-269 after oral administration of NS-304 is 1.1 μg/mL in rats and 9.0 μg/mL in dogs. Selexipag (NS-304) at 1 or 3 mg/kg increases FSBF in anesthetized rats for more than 4 h after intraduodenal administration in a dose-dependent manner. In particular, Selexipag (NS-304) at 3 mg/kg causes a sustained increase in FSBF and exhibits a maximal increase of 93% in FSBF 1 h after administration<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!